Millions invested in Utrecht based companies AM-Pharma and Genmab
AM-Pharma, a clinical stage biopharmaceutical company located in the Utrecht Region, has announced that it has raised €116 million for the development of a treatment for acute kidney injury (AKI). AKI is a devastating disease, with a high mortality rate and no approved pharmacological treatments. AM-Pharma is the leading company in the development of a treatment and will use the funds to carry out a multi-national and pivotal trial for 1,400 patients.
Genmab, another high profile life sciences company on the Utrecht Science Park (USP), has made an important announcement too. The biotech company specializes in development of cancer treatment and plans to raise more than € 450 million by offering shares on the Nasdaq Global Select Market
Together with the € 4,5 billion investment of US biotech giant Gilead in Galapagos N.V., it has been a great week for life sciences community in the Netherlands. It's clear that the Dutch Life Sciences-sector is booming and that it's becoming one of the most interesting ecosystems in the world.